HGEN News and Press, Humanigen Inc. From 02/08/22

Cenexi to Become Preferred Drug Product Supplier for France and the European Union Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine s...

Lenzilumab plus standard of care (SOC), resulted in an estimated cost savings of $13,190 per patient (net savings of $3,190, after an assumed price of $10,000 for lenzilumab) in those receiving remdesivir with baseline C-Reactive Protein (CRP) levels <150 mg/L, and aged <85 year...

FDA Type C meeting and advice creates alignment on registration pathway for Phase 3 clinical development of lenzilumab for the prevention of CAR-T therapy related toxicities including Immune Effector Cell-Associated Neurotoxicity (ICANS) and Cytokine Release Syndrome (CRS) Randomi...

Top-line data from ACTIV-5/BET-B expected to be announced late in the first quarter or early in the second quarter of 2022 ACTIV-5/BET-B results to be shared with regulatory authorities in the US, UK, and EU as part of the ongoing review process Lenzilumab is a variant-agnosti...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that Cameron Durrant, chairman and chief executive officer of Humanigen, wi...

Multi-variate analysis of LIVE-AIR Phase 3 data demonstrates that elevated baseline C-Reactive Protein (“CRP”) is the most predictive feature for progression to invasive mechanical ventilation (“IMV”) or death and may be a useful biomarker to guide therapeu...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that Cameron Durrant, Chairman & CEO, will give a corporate presentatio...

CF Acquisition (NASDAQ:CFVIU) +28% on deal to take conservative video platform Rumble public Phunware (NASDAQ:PHUN) +23%. Digital World Acquisition (NASDAQ:DWAC) +23% on deal to take conservative video platform Rumble public Omeros (NASDAQ:OMER) +18% to sell OMID...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that it will host a conference call and webcast to discuss The Lancet Respi...

Lenzilumab is a variant-agnostic therapeutic that targets the dysregulated host immune response, an approach which may be of greater value than targeting the virus in hospitalized patients 1 Per the paper, the implication from all the available evidence is that “Lenzilu...